Relatlimab

Relatlimab
[[File:|frameless|220px|alt=|]]
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Relatlimab is an experimental immunotherapy drug developed for the treatment of various types of cancer. It is a monoclonal antibody that targets the lymphocyte-activation gene 3 (LAG-3), an immune checkpoint receptor expressed on the surface of T-cells. By inhibiting LAG-3, Relatlimab aims to enhance the immune system's ability to fight cancer.

Mechanism of Action

Relatlimab functions by binding to the LAG-3 receptor on T-cells. LAG-3 is involved in regulating the immune response, and its activation can diminish the ability of T-cells to combat cancer cells effectively. By blocking this receptor, Relatlimab may help in restoring and amplifying the immune response against cancer cells.

Clinical Trials

Relatlimab has been evaluated in several clinical trials, often in combination with other immunotherapeutic agents such as nivolumab, a PD-1 inhibitor. These studies aim to determine the efficacy and safety of Relatlimab in treating various malignancies, including melanoma, non-small cell lung cancer (NSCLC), and more.

Development and Regulatory Status

As of the last update, Relatlimab is still under clinical investigation and has not yet received approval from regulatory bodies such as the Food and Drug Administration (FDA) for general medical use. Ongoing trials continue to assess its potential as a viable cancer treatment.

See Also

• Immunotherapy
• Monoclonal antibodies
• Cancer treatment
• Clinical trial

   This article is a medical stub. You can help WikiMD by expanding it!